<DOC>
	<DOCNO>NCT00914745</DOCNO>
	<brief_summary>About 80 % worldwide population positive HSV antibody . In United States lifetime prevalence recurrent herpes labialis estimate 20 % 40 % , approximately 100 million episode occur country every year . In Switzerland 70 % adult population positive HSV-1 20 % positive HSV-2 . The Herpes simplex virus lipid bilayer ( virus-envelope ) , cause sensitiveness , kind detergent . Within bilayer cholesterol molecule integrate play crucial role virus entry host cell . In vitro experiment clearly show depletion cholesterol HSV-envelope 2- HPßCD inhibit ability virus infect host cell . The aim clinical trial reduce number Herpes labialis relapse provide patient recurrent Herpes labialis real benefit , concern simple mechanism action negligible side effect . Patients problem swallow antiviral pill standard treatment , find 2- HPßCD drug , apply lip , increase patient 's quality life tremendously . - Trial medicinal product</brief_summary>
	<brief_title>Place Controlled Study Treat Recurrent Herpes Labialis .</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<criteria>Inclusion criterion : Patients enrol study fulfill follow inclusion criterion : 1 . 18 50 year old , 2 . Medical history Herpes labialis lesion lips perioral area ( &lt; 1cm border lip ) . 3 . At least eight recurrence labial herpes previous year enrol study . 4 . Ability willingness participate study . 5 . Voluntary write informed consent . Exclusion criterion : Patients fulfill one follow exclusion criterion may enrol study : 1 . Females child bear potential use reliable , medically accept method birth control ( e.g . surgical , intrauterine contraceptive device , birth control pill , double barrier , hormone delivery system implant injectables , condom diaphragm ( combination contraceptive cream , foam , etc. ) . 2 . Pregnant breast feed female , woman plan become pregnant trial . 3 . Medical history immunosuppression radiotherapy , chemo therapy , immunomodulatory drug , HIV . 4 . Participation another clinical study within 30 day prior application 2HPßCD . 5 . Medical history severe disease like hepatitis , renal liver dysfunction , cardiovascular , gastrointestinal , malignant tumor ( ) , psychiatric disorder etc. , might influence assessment conduct trial discretion investigator . 6 . Intake application antiviral prohibit concomitant medication within 30 day prior application 2HPßCD , plan take drug trial . 7 . Use antiinflammatory medication steroid course study . 8 . Eczema herpeticatum history skin disease would predispose eczema herpeticatum . 9 . Any abnormal perioral skin condition . 10 . Known suspected allergic adverse response investigational product ( 2 HPßCD ) excipients ( PEG 400 , PEG 8000 ) . 11 . Inability follow study protocol . 12 . Medical history alcohol and/ drug abuse within previous 12 month enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>